Elevation of small, dense low density lipoprotein cholesterol-a possible antecedent of atherogenic lipoprotein phenotype in type 2 diabetes patients in Jos, North-Central Nigeria.

Autor: Inaku KO; Department of Chemical Pathology, Faculty of Medicine, College of Medical Sciences, University of Calabar, Calabar, Cross River State Nigeria., Ogunkeye OO; Department of Chemical Pathology, Faculty of Medical Sciences, University of Jos, Jos, Plateau State Nigeria., Abbiyesuku FM; Department of Chemical Pathology, Faculty of Medicine, University of Ibadan, Ibadan, Oyo State Nigeria., Chuhwak EK; Department of Internal Medicine, Faculty of Medical Sciences, University of Jos, Jos, Plateau State Nigeria., Isichei CO; Department of Chemical Pathology, Faculty of Medical Sciences, University of Jos, Jos, Plateau State Nigeria., Imoh LC; Department of Chemical Pathology, University of Jos Teaching Hospital, Jos, Plateau State Nigeria., Amadu NO; Department of Chemical Pathology, University of Jos Teaching Hospital, Jos, Plateau State Nigeria., Abu AO; Department of Chemical Pathology, University of Jos Teaching Hospital, Jos, Plateau State Nigeria.
Jazyk: angličtina
Zdroj: BMC clinical pathology [BMC Clin Pathol] 2017 Dec 06; Vol. 17, pp. 26. Date of Electronic Publication: 2017 Dec 06 (Print Publication: 2017).
DOI: 10.1186/s12907-017-0065-9
Abstrakt: Background: The global prevalence of type 2 diabetes is increasing. Dyslipidaemia is a known complication of diabetes mellitus manifesting frequently as cardiovascular diseases and stoke. Elevation of small, dense low density lipoprotein has been recognised as a component of the atherogenic lipoprotein phenotype associated with cardiovascular complications. We speculate that the elevation of this lipoprotein particle may be the antecedent of the atherogenic lipoprotein phenotype. This study therefore aims to determine the pattern of dyslipidaemia among diabetes mellitus patients in Jos, North-Central Nigeria.
Methods: One hundred and seventy-six patients with type 2 diabetes and 154 age-matched controls were studied. The patients with diabetes were regular clinic attenders and had stable glycaemic control. None were on lipid-lowering therapy. Anthropometric indices, blood pressure, and lipids (including total cholesterol, high density lipoprotein cholesterol, and triglyceride) were measured by chemical methods using the Hitachi 902 analyzer. Low density lipoprotein cholesterol was calculated using the Friedewald's equation. Small, dense low density lipoprotein cholesterol, -sdLDL-C was measured using the precipitation method by Hirano et al. Means of the different groups were compared using EPI Info and a P -value of <0.05 was accepted as significant difference.
Results: Total cholesterol, low density lipoprotein cholesterol, triglyceride and small, dense lipoprotein cholesterol were all significantly higher in diabetes patients than controls except high density lipoprotein cholesterol. The percentage of LDL-C as sdLDL-C among the diabetes versus control group was 45% ± 17.79 v 32.0% ± 15.93. Serum sdLDL-C concentration was determined to be 1.45 ± 0.64 among diabetes patients and 0.8 ± 0.54 among control subjects. 75% of diabetes patients had hypertension and were taking blood pressure lowering medications.
Conclusion: The classical atherogenic lipoprotein phenotype was not demonstrated among subjects with type 2 diabetes mellitus in this study, but the elevation of serum small dense low density lipoprotein cholesterol in patients with sustained hypertension suggests the establishment of atherogenic complications among our diabetes patients.
Databáze: MEDLINE
Externí odkaz: